Evaluation of residual disease and TKI duration are predictive factors for molecular recurrence after stopping Imatinib first-line in chronic phase CML Patients
Nicolini, Franck Emmanuel, Dulucq, Stephanie, Boureau, Lisa, Cony-Makhoul, Pascale, Charbonnier, Aude, Escoffre-Barbe, Martine, Rigal-Huguet, Françoise, Coiteux, Valerie, Varet, Bruno, Dubruille, ViviJournal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.CCR-18-3373
Date:
July, 2019
File:
PDF, 1.03 MB
2019